{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T05:51:17Z","timestamp":1775022677680,"version":"3.50.1"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,5,4]],"date-time":"2024-05-04T00:00:00Z","timestamp":1714780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,5,4]],"date-time":"2024-05-04T00:00:00Z","timestamp":1714780800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Ther"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1007\/s40121-024-00970-x","type":"journal-article","created":{"date-parts":[[2024,5,4]],"date-time":"2024-05-04T10:01:38Z","timestamp":1714816898000},"page":"1253-1268","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Efficacy, Safety, and Pharmacokinetics of AZD7442 (Tixagevimab\/Cilgavimab) for Prevention of Symptomatic COVID-19: 15-Month Final Analysis of the PROVENT and STORM CHASER Trials"],"prefix":"10.1007","volume":"13","clinical-trial-number":[{"clinical-trial-number":"nct04625725","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04625972","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Myron J.","family":"Levin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Ustianowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephane","family":"De Wit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rohini","family":"Beavon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jesse","family":"Thissen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seth","family":"Seegobin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kanika","family":"Dey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen A.","family":"Near","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katie","family":"Streicher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandre","family":"Kiazand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark T.","family":"Esser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,5,4]]},"reference":[{"key":"970_CR1","doi-asserted-by":"crossref","unstructured":"Loo YM, McTamney PM, Arends RH, et al. The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in nonhuman primates and has an extended half-life in humans. Sci Trans Med 2022;14(635):eabl8124.","DOI":"10.1126\/scitranslmed.abg8900"},{"issue":"7821","key":"970_CR2","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/s41586-020-2548-6","volume":"584","author":"SJ Zost","year":"2020","unstructured":"Zost SJ, Gilchuk P, Case JB, et al. Potently neutralizing and protective human antibodies against SARS-CoV-2. Nature. 2020;584(7821):443\u20139.","journal-title":"Nature"},{"issue":"23","key":"970_CR3","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1056\/NEJMoa2116620","volume":"386","author":"MJ Levin","year":"2022","unstructured":"Levin MJ, Ustianowski A, De Wit S, et al. Intramuscular AZD7442 (tixagevimab-cilgavimab) for prevention of Covid-19. N Engl J Med. 2022;386(23):2188\u2013200.","journal-title":"N Engl J Med"},{"issue":"7","key":"970_CR4","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1093\/cid\/ciac899","volume":"76","author":"MJ Levin","year":"2023","unstructured":"Levin MJ, Ustianowski A, Thomas S, et al. AZD7442 (tixagevimab\/cilgavimab) for post-exposure prophylaxis of symptomatic COVID-19. Clin Infect Dis. 2023;76(7):1247\u201356.","journal-title":"Clin Infect Dis"},{"key":"970_CR5","unstructured":"United States Food and Drug Administration. Fact sheet for healthcare providers: emergency use authorization for Evusheld\u2122 (tixagevimab co-packaged with cilgavimab). 2023. https:\/\/www.fda.gov\/media\/154701\/download. Accessed Feb 19 2024."},{"issue":"5","key":"970_CR6","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1111\/bjh.18782","volume":"201","author":"R Suribhatla","year":"2023","unstructured":"Suribhatla R, Starkey T, Ionescu MC, Pagliuca A, Richter A, Lee LYW. Systematic review and meta-analysis of the clinical effectiveness of tixagevimab\/cilgavimab for prophylaxis of COVID-19 in immunocompromised patients. Br J Haematol. 2023;201(5):813\u201323.","journal-title":"Br J Haematol"},{"issue":"1","key":"970_CR7","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1056\/NEJMc2214302","volume":"388","author":"M Imai","year":"2023","unstructured":"Imai M, Ito M, Kiso M, et al. Efficacy of antiviral agents against Omicron subvariants BQ.1.1 and XBB. N Engl J Med. 2023;388(1):89\u201391.","journal-title":"New Engl J Med"},{"key":"970_CR8","doi-asserted-by":"crossref","unstructured":"Arora P, Kempf A, Nehlmeier I, et al. Omicron sublineage BQ1.1. resistance to monoclonal antibodies. Lancet Infect Dis. 2022;23(1):S1473\u20133099(22)00733\u20132.","DOI":"10.1016\/S1473-3099(22)00733-2"},{"issue":"12","key":"970_CR9","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1016\/S1473-3099(22)00694-6","volume":"22","author":"Q Wang","year":"2022","unstructured":"Wang Q, Li Z, Ho J, et al. Resistance of SARS-CoV-2 omicron subvariant BA.4.6 to antibody neutralisation. Lancet Infect Dis. 2022;22(12):1666\u20138.","journal-title":"Lancet Infect Dis"},{"key":"970_CR10","unstructured":"United States Food and Drug Administration. FDA announces Evusheld is not currently authorized for emergency use in the U.S. 2023. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-announces-evusheld-not-currently-authorized-emergency-use-us. Accessed Feb 19 2024."},{"issue":"10","key":"970_CR11","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1093\/infdis\/jiad014","volume":"227","author":"P Forte-Soto","year":"2023","unstructured":"Forte-Soto P, Albayaty M, Brooks D, et al. Safety, tolerability and pharmacokinetics of half-life extended severe acute respiratorysyndrome coronavirus 2 neutralizing monoclonal antibodies AZD7442 (tixagevimab-cilgavimab) in healthy adults. J Infect Dis. 2023;227(10):1153\u201363.","journal-title":"J Infect Dis"},{"issue":"12","key":"970_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14787210.2022.2134118","volume":"20","author":"A Ustianowski","year":"2022","unstructured":"Ustianowski A. Tixagevimab\/cilgavimab for prevention and treatment of COVID-19: a review. Expert Rev Anti Infect Ther. 2022;20(12):1\u201311.","journal-title":"Expert Rev Anti Infect Ther"},{"key":"970_CR13","doi-asserted-by":"crossref","unstructured":"Clegg LE, Stepanov O, Schmidt S, et al. 394. Consistency of AZD7442 (cilgavimab\/tixagevimab) pharmacokinetics across prophylaxis and treatment and adult and pediatric participants: application of population pharmacokinetics to enable rapid decision-making during the COVID-19 pandemic. Open Forum Infect Dis. 2023;10(Suppl_2):ofad500.464.","DOI":"10.1093\/ofid\/ofad500.464"},{"issue":"11","key":"970_CR14","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1016\/j.jiac.2023.07.014","volume":"29","author":"H Okada","year":"2023","unstructured":"Okada H, Ishikawa K, Itoh Y, et al. Safety, tolerability, and pharmacokinetics of half-life extended SARS-CoV-2-neutralizing monoclonal antibodies AZD7442 (tixagevimab\/cilgavimab) in healthy Japanese adults. J Infect Chemother. 2023;29(11):1061\u20137.","journal-title":"J Infect Chemother"},{"issue":"10","key":"970_CR15","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1016\/S2213-2600(22)00180-1","volume":"10","author":"H Montgomery","year":"2022","unstructured":"Montgomery H, Hobbs FDR, Padilla F, et al. Efficacy and safety of intramuscular administration of tixagevimab-cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase\u00a03, randomised, double-blind, placebo-controlled trial. Lancet Respir Med. 2022;10(10):985\u201396.","journal-title":"Lancet Respir Med"},{"key":"970_CR16","unstructured":"ClinicalTrials.gov. Study Understanding Pre-Exposure pRophylaxis of NOVel Antibodies (SUPERNOVA). NCT05648110. 2022. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05648110. Accessed Feb 19 2024."},{"issue":"12","key":"970_CR17","doi-asserted-by":"publisher","first-page":"6147","DOI":"10.1128\/AAC.01285-13","volume":"57","author":"GJ Robbie","year":"2013","unstructured":"Robbie GJ, Criste R, Dall\u2019acqua WF, et al. A novel investigational Fc-modified humanized monoclonal antibody, motavizumab-YTE, has an extended half-life in healthy adults. Antimicrob Agents Chemother. 2013;57(12):6147\u201353.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"970_CR18","doi-asserted-by":"publisher","first-page":"e01020","DOI":"10.1128\/AAC.01020-16","volume":"61","author":"XQ Yu","year":"2017","unstructured":"Yu XQ, Robbie GJ, Wu Y, et al. Safety, tolerability, and pharmacokinetics of MEDI4893, an investigational, extended-half-life, anti-Staphylococcus aureus alpha-toxin human monoclonal antibody, in healthy adults. Antimicrob Agents Chemother. 2017;61(1):e01020-e1116.","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"970_CR19","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1056\/NEJMoa2110275","volume":"386","author":"LL Hammitt","year":"2022","unstructured":"Hammitt LL, Dagan R, Yuan Y, et al. Nirsevimab for prevention of RSV in healthy late-preterm and term infants. N Engl J Med. 2022;386(9):837\u201346.","journal-title":"N Engl J Med"}],"container-title":["Infectious Diseases and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-024-00970-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40121-024-00970-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-024-00970-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,27]],"date-time":"2024-05-27T03:28:40Z","timestamp":1716780520000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40121-024-00970-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,4]]},"references-count":19,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["970"],"URL":"https:\/\/doi.org\/10.1007\/s40121-024-00970-x","relation":{},"ISSN":["2193-8229","2193-6382"],"issn-type":[{"value":"2193-8229","type":"print"},{"value":"2193-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,4]]},"assertion":[{"value":"11 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Myron J. Levin reports research support from Johnson & Johnson, Novavax, Moderna, and GSK; consultancy for Merck & Co., GSK, Pfizer, Dynavax and Seqirus; and data safety monitoring\/advisory board for GSK. Andrew Ustianowski reports honoraria\/speaker fees from AstraZeneca, Sanofi, Merck, Janssen, GSK, and Gilead, and advisory boards for Gilead, Merck, Pfizer, and ViiV Healthcare\/GSK. Stephane De Wit reports financial support from AstraZeneca for the conduct of this study. Myron J. Levin, Stephane De Wit, Rohini Beavon, Jesse Thissen, Seth Seegobin, Kanika Dey, Karen A. Near, Katie Streicher, Alexandre Klazand, and Mark T. Esser are employees of, and may hold stock and\/or stock options in, AstraZeneca.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"These studies adhered to Good Clinical Practice guidelines and the Declaration of Helsinki, Council for International Organizations of Medical Sciences International Ethical guidelines, applicable International Conference on Harmonisation Good Clinical Practice guidelines, and all applicable laws and regulations. The protocols were approved by the institutional review boards of the coordinating centers for PROVENT (WIRB Copernicus) and STORM CHASER (Advarra IRB) as well as the institutional review boards or ethics committees at all other participating centers (Supplementary Table\u00a0). All participants provided informed, written consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}